研報掘金丨開源證券:中國巨石有望迎來新一輪增長期,首予“買入”評級
開源證券研報指出,中國巨石(600176.SH)是全球最大的玻璃纖維生產商之一,公司產品涵蓋玻璃纖維製品、熱塑性塑料用玻纖產品、高性能複合纖維等11種品類,實現了從低端到高端的全品類覆蓋。公司產能優勢顯著,產銷量在國內處於領先地位,同時通過優化原材料採購和生產工藝,顯著降低了綜合成本。海外產能充足,擁有多個海外生產基地和完善的銷售網絡,國外業務收入佔比高且盈利能力強。這些優勢不僅提升了公司的市場競爭力,還為其在全球市場的持續擴張奠定了堅實基礎。目前玻纖行業處於歷史底部,但是公司營業收入2024年已呈現觸底企穩趨勢,隨着玻纖價格企穩回升,公司有望迎來新一輪增長期。首次覆蓋給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.